---
document_datetime: 2026-01-27 14:00:19
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imcivree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imcivree-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6254951
conversion_datetime: 2026-01-29 12:17:11.913846
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMCIVREE

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 11/12/2025                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000257063                     | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to update information on immunogenicity and anti-drug antibodies (ADA) as a follow- up to the CHMP Assessment Report for procedure EMEA/H/C/005089/REC/006-007 and based on the updated Integrated Summary of Immunogenicity (ISI).                                                                         |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000280831 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from study RM-493-022. This is a Phase 3 long-term extension trial of setmelanotide (RM-493) for patients who have completed a trial of setmelanotide for the treatment of obesity associated with genetic defects upstream of the melanocortin 4 (MC4) receptor in the leptin-melanocortin pathway. | 13/11/2025 |     |
| Variation type IA / EMA/VR/0000307155 | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality                                                                                                                                                                                                                                                                                                                                                                                                             | 20/10/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                            | control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000257865 | - -                                                                                                                                        |